Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Regenxbio Inc RGNX

Healthcare Biotechnology
REGENXBIO Inc. is a clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. The Company has developed a pipeline of gene therapy programs using its proprietary adeno-associated virus (AAV) gene therapy delivery platform (NAV Technology Platform) to address genetic diseases. The Company is focused on its internal development pipeline in three... see more

Recent & Breaking News (NDAQ:RGNX)

Market Trends Toward New Normal in Keysight Technologies, Alamos Gold, ADT, SecureWorks, REGENXBIO, and Tetra Technologies — Emerging Consolidated Expectations, Analyst Ratings

GlobeNewswire February 4, 2019

REGENXBIO Receives Rare Pediatric Disease Designation for RGX-181 Gene Therapy for the Treatment of CLN2 Form of Batten Disease

PR Newswire January 31, 2019

REGENXBIO to Present at the 37th Annual J.P. Morgan Healthcare Conference

PR Newswire January 4, 2019

REGENXBIO Reports Continued Progress Across Programs in Year-End 2018 Corporate Update

PR Newswire January 3, 2019

Rocket Pharmaceuticals and REGENXBIO Announce New License Agreement for the Treatment of Danon Disease Using NAV AAV9 Vector

Business Wire November 26, 2018

REGENXBIO and Rocket Pharmaceuticals Announce New License Agreement for the Treatment of Danon Disease Using NAV AAV9 Vector

PR Newswire November 26, 2018

FDA Grants Orphan Drug Designation To RGX-181 Gene Therapy For The Treatment Of CLN2 Form Of Batten Disease

PR Newswire November 14, 2018

Consolidated Research: 2018 Summary Expectations for Murphy Oil, REGENXBIO, CRA International,Inc, Carriage Services, CONMED, and BioDelivery Sciences International — Fundamental Analysis, Key Performance Indications

GlobeNewswire November 12, 2018

REGENXBIO Reports Third Quarter 2018 Financial and Operating Results and Announces Initiation of Phase I/II Clinical Trial for RGX-121 for the Treatment of MPS II

PR Newswire November 7, 2018

Alexandria Real Estate Equities, Inc. Announces Development of New Build-to-Suit at the Alexandria Life Science and Translational Research Center at 9800 Medical Center Drive with Signing of 15-Year, 132,000 RSF Lease for REGENXBIO's New HQ and R&D Facili

PR Newswire November 7, 2018

REGENXBIO to Present at Upcoming Investor Conferences

PR Newswire November 6, 2018

REGENXBIO and Abeona Therapeutics Announce Worldwide Exclusive Licenses for the Treatment of Four Rare Lysosomal Storage Disorders Using NAV AAV9 Vector

PR Newswire November 5, 2018

REGENXBIO to Host Conference Call on November 7 to Discuss Third Quarter 2018 Financial Results and Recent Operational Highlights

PR Newswire October 31, 2018

REGENXBIO Announces Additional Positive Interim Phase I Trial Update for RGX-314 for the Treatment of Wet AMD at the American Academy of Ophthalmology 2018 Annual Meeting

PR Newswire October 26, 2018

REGENXBIO Announces Exclusive Worldwide License with Ultragenyx for the Treatment of CDKL5 Deficiency Disorder Using NAV Vectors

PR Newswire October 22, 2018

Detailed Research: Economic Perspectives on Control4, REGENXBIO, Ferro, Kadmon, Hemispherx BioPharma, and Murphy Oil — What Drives Growth in Today's Competitive Landscape

GlobeNewswire October 18, 2018

REGENXBIO Announces Completion of Dosing of Fourth Cohort in Phase I Clinical Trial of RGX-314 Gene Therapy for Wet AMD

PR Newswire October 4, 2018

REGENXBIO to Present at the Chardan 2nd Annual Genetic Medicines Conference

PR Newswire October 2, 2018

REGENXBIO to Present at Upcoming Investor Conferences

PR Newswire September 6, 2018

REGENXBIO Announces Pipeline Expansion with RGX-181 Gene Therapy for CLN2 Form of Batten Disease

PR Newswire August 30, 2018